Our Impact

The Kanzius Noninvasive Radiowave Cancer Treatment is an alternative cancer treatment to current therapies and surgeries, which are known for their dreadful, and often long-lasting, side effects. The Kanzius treatment has displayed the ability to eradicate cancer cells without damaging the healthy surrounding cells, noninvasively and with no side effects using only three basic elements: radiowaves, nanoparticles, and antibodies. When combined to treat cancer, these three simple components create promise for an effective, dignified and groundbreaking alternative to treat cancer patients.

Drown Out Cancer has given patients facing overwhelming circumstances the ability to focus on their health and quality of life rather than face financial burdens. The Drown Out Cancer for Patients in Need fund at The University of Kansas Cancer Center provides 20 hours of private duty care to oncology patients who do not have the financial resources to pay for the cost of private duty care. Since 2013, Drown Out Cancer has provided over $30,000 of support to many oncology patients.

The commitment of Drown Out Cancer can also be seen within the Cambridge North Tower at The University of Kansas Health System. Cambridge North Tower will expand access to highly specialized surgical services for oncology, neurosciences and otolaryngology (ear, nose and throat) and medical oncology. The support received from Drown Out Cancer will help provide the latest technology and innovative treatment options to thousands of critically ill patients annually. We are grateful for Drown Out Cancer’s generosity and dedication to helping us provide the very best care to our cancer patients.

Terry Tsue, MD
Physician-in-Chief
The University of Kansas Cancer Center

I am Professor of Surgery and Chief of Surgical Oncology at the Baylor College of Medicine, in the Dan L. Duncan NCI-Designated Comprehensive Cancer Center and I am also the Oncology Service Line Chief at CHI Baylor St. Luke’s Medical Center. My clinical duties involve providing surgical care for patients with hepatobiliary and gastrointestinal malignancies.  My research laboratory has been involved in design, bench testing, preclinical testing, and clinical testing of new devices which have successfully gone through the full FDA approval process.  The laboratory is currently focused on testing a novel noninvasive radiofrequency (RF) field treatment device.  We are also conjugating nanoparticles to antibodies, peptides, and pharmacologic agents to target them to cancer cells. The laboratory combines physics, chemistry, molecular biology, and bioengineering to produce a state-of-the-art translational approach to novel cancer treatment. Furthermore, we have discovered that many nanoparticles are multifunctional and may be used as optical or radiologic diagnostic materials, in addition to being used as a potential therapeutic agent in the noninvasive RF field. The RF field can also be used to alter the tumor microenvironment to enhance and improve delivery of cytotoxic drugs, biologic agents, nanomaterials, and activated immune system cells without causing damage to adjacent normal tissues. We are performing preclinical studies with this RF system to obtain data to petition the FDA for human clinical trials.

Our projects are currently focused on the following areas:

• Mathematical modeling of electrical and thermodynamic properties of normal and malignant tissues
• Intravital microscopy quantitative and qualitative measurement of RF-induced increases in intratumoral blood flow, delivery of cytotoxic or biologic agents and nanoparticles, and enhanced delivery of cytotoxic or biologic agents and nanoparticles, and enhanced delivery of cytotoxic T cells
• Large animal modeling of RF thermal dosimetry
• Small and large animal RF toxicity studies
• Formulation of carbon-and gold-based nanoparticle delivery vectors using RF field delivery and heating
• Formulation of multi-functional liposomes for targeted drug delivery
• MR thermography real-time with RF treatment
• MR arterial phase sequence measurement of tumor blood flow